- 专利标题： Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment
-
申请号： US14855661申请日： 2015-09-16
-
公开(公告)号： US09789170B2公开(公告)日： 2017-10-17
- 发明人: Richard Showalter , Robert Almassy , James A. Thomson , Wes Sisson , Wei-Jong Shia , Li-Chang Chen , Yang Lee
- 申请人： Polaris Group
- 申请人地址： KY Grand Cayman
- 专利权人： Polaris Group
- 当前专利权人： Polaris Group
- 当前专利权人地址： KY Grand Cayman
- 代理机构： Cooley LLP
- 主分类号： A61K38/43
- IPC分类号： A61K38/43 ; A61K38/50 ; A61K47/48 ; A61K45/06 ; C12N9/78
摘要：
The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer.
公开/授权文献
信息查询
IPC分类:
